Novartis Stock

Novartis Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Novartis (NOVN.SW) as of Aug 25, 2026 is 1.73. In the previous year, Net Debt to Free Cash Flow Ratio was 1.81 — a change of -4.70% (lower).

Net Debt/FCF

1.73

YoY

-4.70%

Last updated:

Net Debt to Free Cash Flow Ratio of Novartis is 2026 1.73 . Net Debt to Free Cash Flow Ratio of Novartis was 2025 1.81 . It decreases by -4.70% lower compared to the previous year.

The Novartis Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
2.15 USD
Jan 1, 2019
2.16 USD
Jan 1, 2020
3.18 USD
Jan 1, 2021
0.83 USD
Jan 1, 2022
1.36 USD
Jan 1, 2023
1.57 USD
Jan 1, 2024
1.81 USD
Jan 1, 2025
1.73 USD
The Novartis Net Debt/FCF history
YEARNet Debt/FCFYoY
1.73-4.70%
1.81+15.38%
1.57+16.04%
1.36+63.91%
0.83-74.02%
3.18+47.21%
2.16+0.60%
2.15-16.57%
2.58+3.84%
2.48-7.00%
2.67+143.82%
1.09
Access this data via the Eulerpool API

Novartis Stock analysis

What does Novartis do? Novartis AG is a globally active company operating in the pharmaceutical, ophthalmology, and generics manufacturing sectors. The company, headquartered in Basel, Switzerland, was founded in 1996 and originated from a merger between Ciba-Geigy and Sandoz. Novartis AG is now a leading company worldwide in the research, development, production, and marketing of pharmaceuticals and other health products. Novartis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novartis stock

Net Debt to Free Cash Flow Ratio of Novartis is 1.73 in 2026.

Net Debt to Free Cash Flow Ratio of Novartis changed from 1.81 to 1.73, representing a -4.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Novartis since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Novartis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Novartis

All Key Metrics — Novartis